Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain activ... Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression and neurodegenerative disorders by using peptide-based and brain active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders. Show more
NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (Nasdaq: PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1938 | -27.1504623144 | 0.7138 | 0.7999 | 0.44 | 702699 | 0.5349097 | CS |
4 | -0.05 | -8.77192982456 | 0.57 | 0.7999 | 0.44 | 362033 | 0.5568801 | CS |
12 | -0.071 | -12.013536379 | 0.591 | 1.09 | 0.44 | 269923 | 0.64618965 | CS |
26 | -0.385 | -42.5414364641 | 0.905 | 1.1099 | 0.44 | 238152 | 0.75461377 | CS |
52 | -0.4 | -43.4782608696 | 0.92 | 1.87 | 0.44 | 125772 | 0.78241112 | CS |
156 | -5.16 | -90.8450704225 | 5.68 | 5.92 | 0.44 | 63706 | 1.63207333 | CS |
260 | -14.44 | -96.5240641711 | 14.96 | 19.56 | 0.44 | 344090 | 10.38772824 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.